What is Recombinant Hirudin Medicine Market?
Recombinant hirudin (lepirudin) is a potent direct thrombin inhibitor, which has been approved for the treatment of heparin-induced thrombocytopenia type II (HIT). Because the drug is mainly eliminated by the kidneys, a single loading dose of hirudin may induce therapeutic anticoagulation for up to one week in patients with renal insufficiency. Thus, the use of hirudin in critically ill patients with renal failure could markedly increase their bleeding risk. In this study, hirudin was used in critically ill patients with suspected HIT while on continuous venovenous hemodialysis (CVVHD).
The market study is being classified by Type (12000 ATU / mg, 16000 ATU / mg, 16000 ATU / mg and Others), by Application (Thrombosis Disease, Tumor Disease and Others) and major geographies with country level break-up.
Abbott (United States), The Medicines Company (United States), Teva Pharmaceutical (Israel), Pfizer (United States) and Pentapharm (Switzerland) are some of the key players profiled in the study.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Recombinant Hirudin Medicine market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Recombinant Hirudin Medicine market by Type, Application and Region.
On the basis of geography, the market of Recombinant Hirudin Medicine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Geriatric Population
- Growing Advancement in Medical Sector
- Price of Medicine is Costly and Also Limited in Stock
- Growing Government Support to Medical Sector
- Low Awareness About this Medicine in Various Region
Key Target AudienceRecombinant Hirudin Medicine Providers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase